Colorectal Cancer Screening: Education, Advocacy, and Action
It is essential to continue to develop and incorporate educational strategies to increase screening for colorectal cancer in our communities.
Developing a High-Risk Cancer Prevention and Wellness Program to Meet Community Needs
The program’s initiative aims to identify those at increased risk for cancer through assessment and testing and then formulate a personalized evidence-based cancer surveillance or screening plan.
CMS Predicts Health Care Spending Will Top $7 Trillion by 2031
It is anticipated that health care spending will grow by an annual average of 5.4% over the next 8 years.
Where Did All the Chemotherapy Go?
As we continue to slowly recover from the trauma of the COVID-19 pandemic, we are facing a new problem: chemotherapy shortages.
Improving Palliative Care Referrals Across Oncology
Oncology nurses across the country are spearheading initiatives to improve education, attitudes, and access surrounding palliative care.
Nurses on the Front Lines Are Helping Patients Navigate Brain Tumor Cancer Care
A brain tumor diagnosis can be daunting. Nurses are on the front lines connecting patients to available resources and walking them through the best treatment options.
CDK4/6 Inhibitors May Be Better Suited in the Second-Line for Patients With ER+, HER2– Breast Cancer
Second-line treatment with CDK4/6 inhibition was associated with fewer toxicities and drug costs than frontline CDK4/6 inhibitor treatment—although progression-free survival and overall survival outcomes were similar.
FDA Approves Talazoparib In Combination With Enzalutamide for mCRPC
The PARP inhibitor talazoparib has been approved in combination with enzalutamide for the treatment of adult patients with homologous recombination repair gene–mutated metastatic castration-resistant prostate cancer.
Lauren Mahon Offers Nurse Perspectives on PARP Inhibitors As Ovarian Cancer Maintenance Therapy
Lauren Mahon, MSN, FNP-BC, breaks down what oncology nurses should know about PARP inhibitors in ovarian cancer.
Frontline Enfortumab Vedotin/Pembrolizumab Shows Continued Efficacy in Advanced Urothelial Carcinoma at 4-Year Follow-Up
Enfortumab vedotin plus pembrolizumab elicited durable responses in patients with locally advanced or metastatic urothelial carcinoma who were ineligible for cisplatin.
TROPiCS-02 Final OS Analysis Shows Superior Outcomes With Sacituzumab Govitecan For HR+/HER2– Breast Cancer
Sacituzumab govitecan improved overall survival vs treatment of physician’s choice in pretreated, endocrine-resistant, hormone receptor–positive, HER2-negative metastatic breast cancer.
Trastuzumab Deruxtecan Demonstrates Clinical Activity Across Numerous HER2+ Solid Tumors
In the phase 2 DESTINY-PanTumor02 trial, trastuzumab deruxtecan elicited clinical activity across a range of HER2 expressing solid tumors.
Vorasidenib Demonstrates PFS Benefit in IDH-Mutant Low-Grade Glioma
Vorasidenib reduced the risk of progression or death by 61% compared with placebo for patients with grade 2 IDH-mutant glioma.
Epcoritamab Obtains Accelerated Approval for Relapsed/Refractory DLBCL
The FDA has granted epcoritamab accelerated approval for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma. The prescribing label comes with boxed warnings for cytokine release syndrome and neurologic problems.
Olanzapine Significantly Reduces CINV in Patients Receiving MEC
Reimagining Frailty Screenings in Head and Neck Cancer
Screening for Pain and Depression is Not Enough in Cancer Care
Niraparib-Based Triplet Therapy Offers OS Advantage in BRCA1/2+ mCRPC
2 Clarke Drive Cranbury, NJ 08512